Podcasts about advanced nsclc

  • 41PODCASTS
  • 153EPISODES
  • 29mAVG DURATION
  • 1MONTHLY NEW EPISODE
  • Sep 12, 2024LATEST

POPULARITY

20172018201920202021202220232024


Best podcasts about advanced nsclc

Latest podcast episodes about advanced nsclc

Research To Practice | Oncology Videos
Non-Small Cell Lung Cancer with an EGFR Mutation | Striving for Consensus: Current and Future Management of Non-Small Cell Lung Cancer with an EGFR Mutation

Research To Practice | Oncology Videos

Play Episode Listen Later Sep 12, 2024 123:01


Featuring slide presentations and related discussion from Dr Pasi A Jänne, Prof Tom John, Dr Zofia Piotrowska and Dr Alexander I Spira, including the following topics: Recent Advances in the Management of Localized and Locally Advanced Non-Small Cell Lung Cancer (NSCLC) with an EGFR Mutation — Prof John (0:00) First-Line Treatment for Advanced NSCLC with an EGFR Mutation — Dr Spira  (32:48) Later-Line Therapy for Advanced NSCLC with an EGFR Mutation — Dr Jänne (1:03:51) Management of NSCLC with an EGFR Exon 20 Mutation — Dr Piotrowska (1:33:33) CME information and select publications

CCO Oncology Podcast
Available and Emerging Therapies for Progressive/Recurrent ROS1-Altered Advanced NSCLC

CCO Oncology Podcast

Play Episode Listen Later Sep 6, 2024 13:53


In this episode, listen to Alice T. Shaw, MD, PhD, and Jessica J. Lin, MD, share their thoughts on the available and emerging clinical data for second-line and beyond treatments in patients with recurrent ROS1-altered advanced NSCLC including:Assessing ROS1-TKI resistance mutations with tumor and liquid biopsies in patients with ROS1-altered advanced NSCLCPrevious TKI-treated cohort from the TRIDENT-1 study: efficacy of repotrectinib in patients with recurrent ROS1-altered NSCLC and measurable baseline brain metastases   Phase II TRUST-1 trial of taletrectinib: activity in patients with known ROS1 G2032R resistance mutation ROS1-altered advanced NSCLCThe global phase I/II ARROS-1 study of zidesamtinib (NVL-520): safety summary in patients with ROS1-altered advanced NSCLC  Program faculty:Jessica J. Lin, MDAttending PhysicianMassachusetts General HospitalAssociate Professor of MedicineHarvard Medical SchoolBoston, MassachusettsAlice T. Shaw, MD, PhDChief, Strategic PartnershipsAttending Physician, Thoracic OncologyDana-Farber Cancer InstituteHarvard Medical SchoolBoston, MassachusettsResources:To download the slides associated with this podcast discussion, please visit the program page.

CCO Oncology Podcast
Available Clinical Data and Approved First-line Treatments for ROS1-Altered Advanced NSCLC

CCO Oncology Podcast

Play Episode Listen Later Sep 5, 2024 13:46


In this episode, listen to Alice T. Shaw, MD, PhD, and Jessica J. Lin, MD, share their thoughts on the available clinical data in support of frontline treatments for ROS1-altered NSCLC including:Efficacy and safety data for crizotinib, entrectinib, and repotrectinib in patients with ROS1-altered advanced NSCLCLong-term safety observations for crizotinib and entrectinib CNS activity of entrectinib and repotrectinib in patients with brain metastasesRepotrectinib activity in ROS1-TKI resistance mutations  Program faculty:Jessica J. Lin, MDAttending PhysicianMassachusetts General HospitalAssociate Professor of MedicineHarvard Medical SchoolBoston, MassachusettsAlice T. Shaw, MD, PhDChief, Strategic PartnershipsAttending Physician, Thoracic OncologyDana-Farber Cancer InstituteHarvard Medical SchoolBoston, MassachusettsResources:To download the slides associated with this podcast discussion, please visit the program page.

CCO Oncology Podcast
ROS1-Alterations and Molecular Testing in Advanced NSCLC

CCO Oncology Podcast

Play Episode Listen Later Aug 28, 2024 16:28


In this episode, listen to Alice T. Shaw, MD, PhD, and Jessica J. Lin, MD, share their thoughts on the current understanding of ROS1 rearrangements in non-small-cell lung cancer tumor biology and its implications for molecular testing and treatment selection including:ROS1-gene fusions in advanced lung cancerROS1 testing recommendations with DNA NGS, RNA NGS, FISH break apart assay, and IHCComparative specificity of ROS1 and ALK targeting tyrosine kinase inhibitorsAdvantages of RNA- vs DNA-based next-generation sequencing Program faculty:Jessica J. Lin, MDAttending PhysicianMassachusetts General HospitalAssociate Professor of MedicineHarvard Medical SchoolBoston, MassachusettsAlice T. Shaw, MD, PhDChief, Strategic PartnershipsAttending Physician, Thoracic OncologyDana-Farber Cancer InstituteHarvard Medical SchoolBoston, MassachusettsResources:To download the slides associated with this podcast discussion, please visit the program page

ReachMD CME
HER2-Targeted ADCs in Advanced NSCLC: A Case-Based Approach to Targeted Treatment for Metastatic Disease

ReachMD CME

Play Episode Listen Later Aug 13, 2024


CME credits: 0.50 Valid until: 13-08-2025 Claim your CME credit at https://reachmd.com/programs/cme/her2-targeted-adcs-in-advanced-nsclc-a-case-based-approach-to-targeted-treatment-for-metastatic-disease/26285/ The treatment landscape of non-small cell lung cancer (NSCLC) has dramatically changed over the past 20 years. In recent years, the discovery of targetable molecular alterations and the development of targeted therapies have dramatically changed the treatment outlook for NSCLC. Human epidermal growth factor receptor 2 (HER2), also known as ErbB2, is a receptor tyrosine kinase encoded by the ERBB2 proto-oncogene. Its activation affects downstream signaling pathways implicated in cell proliferation, survival, differentiation, and migration. The inclusion of HER2-directed antibody-drug conjugate (ADC) therapy in lung cancer is relatively new; these agents have been shown to greatly improve outcomes in patients with HER2-expressing NSCLC. In this case-based activity, expert faculty illustrate best practices for the use of HER2-directed ADCs in NSCLC.=

PVRoundup Podcast
Lorlatinib shows unprecedented success in advanced NSCLC

PVRoundup Podcast

Play Episode Listen Later Jun 11, 2024 4:43


Which drug keeps lung cancer from progressing for over 5 years? Find out about this and more in today's PeerDirect Medical News Podcast.

Oncology Times - OT Broadcasts from the iPad Archives
mRNA Vaccine + Checkpoint Inhibitor Combo Had Low Toxicity With Evidence of Efficacy in Advanced NSCLC

Oncology Times - OT Broadcasts from the iPad Archives

Play Episode Listen Later May 29, 2024 8:21


A combination of a new mRNA vaccine used together with a programmed death-ligand 1 (PD-L1) immune checkpoint inhibitor to treat patients with lung cancer was markedly less toxic than a combination of the same vaccine with chemotherapy. However, it was apparently just effective. This is according to findings from a study reported to the 2024 AACR Annual Meeting. The randomized study, led by the researchers at the Moffitt Cancer Center, looked at a combination of the mRNA-based active cancer vaccine BI1361849 combined with the anti-PD-L1 checkpoint inhibitor durvalumab with or without the anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) checkpoint inhibitor tremelimumab immunotherapy. After announcing the findings at the AACR, presenting author Dung-Tsa Chen, PhD, Senior Member in the Department of Biostatistics & Informatics, Special Clinical Trial Design, and Data Analysis at the Moffitt Cancer Center, called in to discuss the new data with OncTimesTalk correspondent Peter Goodwin.

PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast
Joshua Sabari, MD - Mastering the Testing for Common and Uncommon EGFR Mutations to Guide EGFR-Targeted Therapy in Advanced NSCLC

PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast

Play Episode Listen Later Feb 9, 2024 41:58


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC information, and to apply for credit, please visit us at PeerView.com/KYJ865. CME/MOC/CC credit will be available until January 24, 2025.Mastering the Testing for Common and Uncommon EGFR Mutations to Guide EGFR-Targeted Therapy in Advanced NSCLC In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThe activity is supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerJoshua Sabari, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Abbvie Inc.; AstraZeneca; Genentech, Inc.; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Mirati Therapeutics, Inc.; Navire; Pfizer; Regeneron Pharmaceuticals Inc.; Sanofi Genzyme; and Takeda Pharmaceutical Company Limited.Grant/Research Support from Boehringer Ingelheim Pharmaceuticals, Inc.; Janssen Pharmaceuticals, Inc.; Mirati Therapeutics, Inc.; and Regeneron Pharmaceuticals Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
Joshua Sabari, MD - Mastering the Testing for Common and Uncommon EGFR Mutations to Guide EGFR-Targeted Therapy in Advanced NSCLC

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Feb 9, 2024 42:09


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC information, and to apply for credit, please visit us at PeerView.com/KYJ865. CME/MOC/CC credit will be available until January 24, 2025.Mastering the Testing for Common and Uncommon EGFR Mutations to Guide EGFR-Targeted Therapy in Advanced NSCLC In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThe activity is supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerJoshua Sabari, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Abbvie Inc.; AstraZeneca; Genentech, Inc.; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Mirati Therapeutics, Inc.; Navire; Pfizer; Regeneron Pharmaceuticals Inc.; Sanofi Genzyme; and Takeda Pharmaceutical Company Limited.Grant/Research Support from Boehringer Ingelheim Pharmaceuticals, Inc.; Janssen Pharmaceuticals, Inc.; Mirati Therapeutics, Inc.; and Regeneron Pharmaceuticals Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast
Joshua Sabari, MD - Mastering the Testing for Common and Uncommon EGFR Mutations to Guide EGFR-Targeted Therapy in Advanced NSCLC

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast

Play Episode Listen Later Feb 9, 2024 41:58


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC information, and to apply for credit, please visit us at PeerView.com/KYJ865. CME/MOC/CC credit will be available until January 24, 2025.Mastering the Testing for Common and Uncommon EGFR Mutations to Guide EGFR-Targeted Therapy in Advanced NSCLC In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThe activity is supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerJoshua Sabari, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Abbvie Inc.; AstraZeneca; Genentech, Inc.; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Mirati Therapeutics, Inc.; Navire; Pfizer; Regeneron Pharmaceuticals Inc.; Sanofi Genzyme; and Takeda Pharmaceutical Company Limited.Grant/Research Support from Boehringer Ingelheim Pharmaceuticals, Inc.; Janssen Pharmaceuticals, Inc.; Mirati Therapeutics, Inc.; and Regeneron Pharmaceuticals Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

PeerView Internal Medicine CME/CNE/CPE Video Podcast
Joshua Sabari, MD - Mastering the Testing for Common and Uncommon EGFR Mutations to Guide EGFR-Targeted Therapy in Advanced NSCLC

PeerView Internal Medicine CME/CNE/CPE Video Podcast

Play Episode Listen Later Feb 9, 2024 41:58


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC information, and to apply for credit, please visit us at PeerView.com/KYJ865. CME/MOC/CC credit will be available until January 24, 2025.Mastering the Testing for Common and Uncommon EGFR Mutations to Guide EGFR-Targeted Therapy in Advanced NSCLC In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThe activity is supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerJoshua Sabari, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Abbvie Inc.; AstraZeneca; Genentech, Inc.; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Mirati Therapeutics, Inc.; Navire; Pfizer; Regeneron Pharmaceuticals Inc.; Sanofi Genzyme; and Takeda Pharmaceutical Company Limited.Grant/Research Support from Boehringer Ingelheim Pharmaceuticals, Inc.; Janssen Pharmaceuticals, Inc.; Mirati Therapeutics, Inc.; and Regeneron Pharmaceuticals Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

PeerView Internal Medicine CME/CNE/CPE Audio Podcast
Joshua Sabari, MD - Mastering the Testing for Common and Uncommon EGFR Mutations to Guide EGFR-Targeted Therapy in Advanced NSCLC

PeerView Internal Medicine CME/CNE/CPE Audio Podcast

Play Episode Listen Later Feb 9, 2024 42:09


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC information, and to apply for credit, please visit us at PeerView.com/KYJ865. CME/MOC/CC credit will be available until January 24, 2025.Mastering the Testing for Common and Uncommon EGFR Mutations to Guide EGFR-Targeted Therapy in Advanced NSCLC In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThe activity is supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerJoshua Sabari, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Abbvie Inc.; AstraZeneca; Genentech, Inc.; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Mirati Therapeutics, Inc.; Navire; Pfizer; Regeneron Pharmaceuticals Inc.; Sanofi Genzyme; and Takeda Pharmaceutical Company Limited.Grant/Research Support from Boehringer Ingelheim Pharmaceuticals, Inc.; Janssen Pharmaceuticals, Inc.; Mirati Therapeutics, Inc.; and Regeneron Pharmaceuticals Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast
Joshua Sabari, MD - Mastering the Testing for Common and Uncommon EGFR Mutations to Guide EGFR-Targeted Therapy in Advanced NSCLC

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Feb 9, 2024 42:09


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC information, and to apply for credit, please visit us at PeerView.com/KYJ865. CME/MOC/CC credit will be available until January 24, 2025.Mastering the Testing for Common and Uncommon EGFR Mutations to Guide EGFR-Targeted Therapy in Advanced NSCLC In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThe activity is supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerJoshua Sabari, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Abbvie Inc.; AstraZeneca; Genentech, Inc.; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Mirati Therapeutics, Inc.; Navire; Pfizer; Regeneron Pharmaceuticals Inc.; Sanofi Genzyme; and Takeda Pharmaceutical Company Limited.Grant/Research Support from Boehringer Ingelheim Pharmaceuticals, Inc.; Janssen Pharmaceuticals, Inc.; Mirati Therapeutics, Inc.; and Regeneron Pharmaceuticals Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

PeerView Heart, Lung & Blood CME/CNE/CPE Audio Podcast
Joshua Sabari, MD - Mastering the Testing for Common and Uncommon EGFR Mutations to Guide EGFR-Targeted Therapy in Advanced NSCLC

PeerView Heart, Lung & Blood CME/CNE/CPE Audio Podcast

Play Episode Listen Later Feb 9, 2024 42:09


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC information, and to apply for credit, please visit us at PeerView.com/KYJ865. CME/MOC/CC credit will be available until January 24, 2025.Mastering the Testing for Common and Uncommon EGFR Mutations to Guide EGFR-Targeted Therapy in Advanced NSCLC In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThe activity is supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerJoshua Sabari, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Abbvie Inc.; AstraZeneca; Genentech, Inc.; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Mirati Therapeutics, Inc.; Navire; Pfizer; Regeneron Pharmaceuticals Inc.; Sanofi Genzyme; and Takeda Pharmaceutical Company Limited.Grant/Research Support from Boehringer Ingelheim Pharmaceuticals, Inc.; Janssen Pharmaceuticals, Inc.; Mirati Therapeutics, Inc.; and Regeneron Pharmaceuticals Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

PeerView Clinical Pharmacology CME/CNE/CPE Video
Joshua Sabari, MD - Mastering the Testing for Common and Uncommon EGFR Mutations to Guide EGFR-Targeted Therapy in Advanced NSCLC

PeerView Clinical Pharmacology CME/CNE/CPE Video

Play Episode Listen Later Feb 9, 2024 41:58


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC information, and to apply for credit, please visit us at PeerView.com/KYJ865. CME/MOC/CC credit will be available until January 24, 2025.Mastering the Testing for Common and Uncommon EGFR Mutations to Guide EGFR-Targeted Therapy in Advanced NSCLC In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThe activity is supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerJoshua Sabari, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Abbvie Inc.; AstraZeneca; Genentech, Inc.; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Mirati Therapeutics, Inc.; Navire; Pfizer; Regeneron Pharmaceuticals Inc.; Sanofi Genzyme; and Takeda Pharmaceutical Company Limited.Grant/Research Support from Boehringer Ingelheim Pharmaceuticals, Inc.; Janssen Pharmaceuticals, Inc.; Mirati Therapeutics, Inc.; and Regeneron Pharmaceuticals Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Practice Point Communications
Conversations in Advanced NSCLC: Rationale and Utility of TROP2 Antibody-Drug Conjugates Based on Updates from WCLC and ESMO - Episode 1

Practice Point Communications

Play Episode Listen Later Dec 29, 2023 16:19


This podcast series, lead by expert faculty, inform and guide the safety and efficacy of TROP2-directed ADCs in different settings of NSCLC treatment that was reported at key conferences such as the World Conference on Lung Cancer (WCLC 2023) and European Society of Medical Oncology (ESMO 2023) annual conference. The expert faculty will also discuss insights into using agents upon availability to enable improved outcomes among distinct subsets of patients.Launch Date: December 29, 2023Release Date: December 29, 2023Expiration Date: November 30, 2024FACULTY BIOSBenjamin Levy, MDAssociate Professor of OncologyJohns Hopkins MedicineAaron Lisberg, MDAssistant Professor of Clinical MedicineUniversity of California, Los AngelesAlexander Spira, MD, PhD, FACPCo-DirectorVirginia Cancer Specialists Research InstituteThis podcast provides accredited continuing education credits. To qualify for credit, please read all accreditation information at the provided link below prior to listening to this episode.https://www.practicepointcme.com/CMEHome/conversations-in-advanced-nsclc-rationale-and-utility-of-trop2-antibody-drug-conjugates-based-on-updates-from-wclc-and-esmo-1

Practice Point Communications
Conversations in Advanced NSCLC: Rationale and Utility of TROP2 Antibody-Drug Conjugates Based on Updates from WCLC and ESMO - Episode 2

Practice Point Communications

Play Episode Listen Later Dec 29, 2023 12:47


This podcast series, lead by expert faculty, inform and guide the safety and efficacy of TROP2-directed ADCs in different settings of NSCLC treatment that was reported at key conferences such as the World Conference on Lung Cancer (WCLC 2023) and European Society of Medical Oncology (ESMO 2023) annual conference. The expert faculty will also discuss insights into using agents upon availability to enable improved outcomes among distinct subsets of patients.Launch Date: December 29, 2023Release Date: December 29, 2023Expiration Date: November 30, 2024FACULTY BIOSBenjamin Levy, MDAssociate Professor of OncologyJohns Hopkins MedicineAaron Lisberg, MDAssistant Professor of Clinical MedicineUniversity of California, Los AngelesAlexander Spira, MD, PhD, FACPCo-DirectorVirginia Cancer Specialists Research InstituteThis podcast provides accredited continuing education credits. To qualify for credit, please read all accreditation information at the provided link below prior to listening to this episode.https://www.practicepointcme.com/CMEHome/conversations-in-advanced-nsclc-rationale-and-utility-of-trop2-antibody-drug-conjugates-based-on-updates-from-wclc-and-esmo-1

Practice Point Communications
Conversations in Advanced NSCLC: Rationale and Utility of TROP2 Antibody-Drug Conjugates Based on Updates from WCLC and ESMO - Episode 3

Practice Point Communications

Play Episode Listen Later Dec 29, 2023 17:46


This podcast series, lead by expert faculty, inform and guide the safety and efficacy of TROP2-directed ADCs in different settings of NSCLC treatment that was reported at key conferences such as the World Conference on Lung Cancer (WCLC 2023) and European Society of Medical Oncology (ESMO 2023) annual conference. The expert faculty will also discuss insights into using agents upon availability to enable improved outcomes among distinct subsets of patients.Launch Date: December 29, 2023Release Date: December 29, 2023Expiration Date: November 30, 2024FACULTY BIOSBenjamin Levy, MDAssociate Professor of OncologyJohns Hopkins MedicineAaron Lisberg, MDAssistant Professor of Clinical MedicineUniversity of California, Los AngelesAlexander Spira, MD, PhD, FACPCo-DirectorVirginia Cancer Specialists Research InstituteThis podcast provides accredited continuing education credits. To qualify for credit, please read all accreditation information at the provided link below prior to listening to this episode.https://www.practicepointcme.com/CMEHome/conversations-in-advanced-nsclc-rationale-and-utility-of-trop2-antibody-drug-conjugates-based-on-updates-from-wclc-and-esmo-1

Keeping Current
Advanced NSCLC: Multidisciplinary and Patient Thoughts on How to Ease the Burden of Care

Keeping Current

Play Episode Listen Later Dec 21, 2023 32:40


How equipped are you in taking a patient-first approach and prioritizing the needs of the patient and their caregivers? Credit available for this activity expires: 12/19/24 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/999304?ecd=bdc_podcast_libsyn_mscpedu

Keeping Current CME
ROS1-Positive Advanced NSCLC: Sharing Best Practice From the Clinic to Maximize Patient Outcomes

Keeping Current CME

Play Episode Listen Later Nov 30, 2023 31:34


How confident are you in managing patients your patients on ROS1 inhibitor therapy? Credit available for this activity expires: 11/30/24 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/998606?ecd=bdc_podcast_libsyn_mscpedu

Oncology Brothers
ESMO 2023 Lung Cancer - Chapter 2 Highlights – PAPILLON, MARIPOSA, MARIPOSA-2, LIBRETTO-431

Oncology Brothers

Play Episode Listen Later Nov 13, 2023 18:28


In discussion with Dr. Alexander Spira, covering the ESMO 2023 Lung Cancer Highlights from Community Oncology perspective. We covered 4 important practice informing studies with Dr. Spira: - PAPILLON – Amivantamab Plus Chemo in Advanced NSCLC with EGFR Exon 20 Insertions - MARIPOSA – Amivantamab Plus Lazertinib Versus Osimertinib as First-line Treatment in EGFR-mutated Advanced NSCLC - MARIPOSA-2 – Amivantamab Plus Chemo (with or without Lazertinib) vs Chemo in EGFR-mutated Advanced NSCLC After Progression on Osimertinib - LIBRETTO-431 – First-line Selpercatinib or Chemo and Pembrolizumab in RET Fusion-Positive Advanced NSCLC

ReachMD CME
Highlights from Madrid on Targeted Therapy for Advanced NSCLC

ReachMD CME

Play Episode Listen Later Sep 25, 2023


CME credits: 1.25 Valid until: 15-11-2024 Claim your CME credit at https://reachmd.com/programs/cme/highlights-from-madrid-on-targeted-therapy-for-advanced-nsclc/16129/ The treatment options for non-small cell lung cancer (NSCLC) are constantly evolving, making it challenging for healthcare professionals to stay updated with the latest scientific evidence. This program aims to address this challenge by bringing together esteemed faculty members who will discuss pivotal scientific advances and practice-altering information related to the use of systemic immunotherapy, targeted therapies, and perioperative immunotherapy in the management of NSCLC across all disease stages.

CME in Minutes: Education in Primary Care
Eric K. Singhi, MD / Charu Aggarwal, MD, MPH - It Takes Two to Tango: Exploring the Clinical Implications of First-Line Immunotherapy Plus Chemotherapy Combinations in Advanced NSCLC

CME in Minutes: Education in Primary Care

Play Episode Listen Later Sep 5, 2023 16:27


Please visit answersincme.com/ZRV860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, two experts in lung carcinoma discuss the latest data in first-line chemoimmunotherapy for non–small-cell lung cancer.Upon completion of this activity, participants should be better able to: Outline which patients might align with first-line chemoimmunotherapy regimens for advanced NSCLC; Review the clinical profiles of chemoimmunotherapy regimens in the first-line setting for the treatment of advanced NSCLC; and Translate the latest data informing the use of first-line chemoimmunotherapy regimens to individualized care of patients with advanced NSCLC.

New FDA Approvals
New MS Biosimilar, RSV Maternal Immunization, Rybrevant in Advanced NSCLC, Xtandi in Early PCa

New FDA Approvals

Play Episode Listen Later Aug 28, 2023 8:29


Summary: In this week's New FDA Approval's podcast episode, Dr. Emma Hitt Nichols discusses the latest FDA approvals from August 21, 2023 – August  25, 2023.  Please check back every Monday morning so that you can stay up to date. See more details summaries and links to prescribing information at nascentmc.com/podcast Here are the highlights:  FDA Approves Tyruko as First Biosimilar to TysabriThe FDA approved Tyruko as the first biosimilar to Tysabri for treating relapsing forms of MS in adults. It has similar risks and side effects as Tysabri and is also approved for treating certain Crohn's Disease patients. The product is available from Sandoz Inc. Source Abrysvo RSV Maternal Immunization ApprovedThe FDA approved Abrysvo, a vaccine for preventing respiratory disease caused by RSV in infants through maternal immunization. The approval is based on Phase 3 MATISSE trial results. Abrysvo was also approved for older adults earlier this year. Source sBLA Filed for Rybrevant in Advanced NSCLCAn sBLA was filed for expanded approval of Rybrevant, combined with certain drugs, for treating advanced non–small cell lung cancer with EGFR exon 20 insertion mutations. The approval was granted to Janssen Pharmaceuticals. Source Priority Review of Xtandi in Early PCaXtandi received Priority Review by the FDA for an expanded use in early-stage prostate cancer. The sNDA is based on a Phase 3 EMBARK trial, where Xtandi showed significant benefits. The product is manufactured by Pfizer, Inc.  Intro and outro music Garden Of Love by Pk jazz Collective    

PeerVoice Oncology & Haematology Video
Barbara Melosky, MD, FRCPC - Navigating Recent Updates With Immunotherapy for Advanced NSCLC: Guidance to Optimize Treatment Decisions

PeerVoice Oncology & Haematology Video

Play Episode Listen Later Jun 28, 2023 11:03


Barbara Melosky, MD, FRCPC - Navigating Recent Updates With Immunotherapy for Advanced NSCLC: Guidance to Optimize Treatment Decisions

PeerVoice Oncology & Haematology Audio
D. Ross Camidge, MD, PhD - Mastering MET and cMET and Recognizing Their Role in Advanced NSCLC

PeerVoice Oncology & Haematology Audio

Play Episode Listen Later Jun 27, 2023 55:27


D. Ross Camidge, MD, PhD - Mastering MET and cMET and Recognizing Their Role in Advanced NSCLC

PeerVoice Oncology & Haematology Video
D. Ross Camidge, MD, PhD - Mastering MET and cMET and Recognizing Their Role in Advanced NSCLC

PeerVoice Oncology & Haematology Video

Play Episode Listen Later Jun 27, 2023 55:24


D. Ross Camidge, MD, PhD - Mastering MET and cMET and Recognizing Their Role in Advanced NSCLC

PeerVoice Heart & Lung Audio
D. Ross Camidge, MD, PhD - Mastering MET and cMET and Recognizing Their Role in Advanced NSCLC

PeerVoice Heart & Lung Audio

Play Episode Listen Later Jun 27, 2023 55:27


D. Ross Camidge, MD, PhD - Mastering MET and cMET and Recognizing Their Role in Advanced NSCLC

PeerVoice Internal Medicine Audio
D. Ross Camidge, MD, PhD - Mastering MET and cMET and Recognizing Their Role in Advanced NSCLC

PeerVoice Internal Medicine Audio

Play Episode Listen Later Jun 27, 2023 55:27


D. Ross Camidge, MD, PhD - Mastering MET and cMET and Recognizing Their Role in Advanced NSCLC

OncLive® On Air
S8 Ep53: Reuss Reviews the Development of LP-300 in Advanced NSCLC

OncLive® On Air

Play Episode Listen Later Jun 19, 2023 10:21


Dr Reuss discusses the development of LP-300 in advanced NSCLC, the mechanisms of LP-300 that may help synergize with the activity of platinum-based chemotherapy, and its ongoing investigation in the phase 2 HARMONIC trial.

PeerVoice Clinical Pharmacology Audio
Expert Guidance for Improving Outcomes in Advanced NSCLC: Utilising ADCs in Practice

PeerVoice Clinical Pharmacology Audio

Play Episode Listen Later Oct 3, 2022 24:30


Expert Guidance for Improving Outcomes in Advanced NSCLC: Utilising ADCs in Practice

PeerVoice Oncology & Haematology Audio
Expert Guidance for Improving Outcomes in Advanced NSCLC: Utilising ADCs in Practice

PeerVoice Oncology & Haematology Audio

Play Episode Listen Later Oct 3, 2022 24:30


Expert Guidance for Improving Outcomes in Advanced NSCLC: Utilising ADCs in Practice

PeerVoice Heart & Lung Audio
Expert Guidance for Improving Outcomes in Advanced NSCLC: Utilising ADCs in Practice

PeerVoice Heart & Lung Audio

Play Episode Listen Later Oct 3, 2022 24:30


Expert Guidance for Improving Outcomes in Advanced NSCLC: Utilising ADCs in Practice

PeerVoice Oncology & Haematology Video
Expert Guidance for Improving Outcomes in Advanced NSCLC: Utilising ADCs in Practice

PeerVoice Oncology & Haematology Video

Play Episode Listen Later Oct 3, 2022 24:14


Expert Guidance for Improving Outcomes in Advanced NSCLC: Utilising ADCs in Practice

PeerVoice Clinical Pharmacology Audio
Right Drug, Right Patient, Right Time: Cases in “Precisionalised” Treatment of Advanced NSCLC

PeerVoice Clinical Pharmacology Audio

Play Episode Listen Later Sep 29, 2022 27:59


Right Drug, Right Patient, Right Time: Cases in “Precisionalised” Treatment of Advanced NSCLC

PeerVoice Oncology & Haematology Video
Right Drug, Right Patient, Right Time: Cases in “Precisionalised” Treatment of Advanced NSCLC

PeerVoice Oncology & Haematology Video

Play Episode Listen Later Sep 29, 2022 27:59


Right Drug, Right Patient, Right Time: Cases in “Precisionalised” Treatment of Advanced NSCLC

PeerVoice Oncology & Haematology Audio
Right Drug, Right Patient, Right Time: Cases in “Precisionalised” Treatment of Advanced NSCLC

PeerVoice Oncology & Haematology Audio

Play Episode Listen Later Sep 29, 2022 27:59


Right Drug, Right Patient, Right Time: Cases in “Precisionalised” Treatment of Advanced NSCLC

PeerVoice Heart & Lung Audio
Right Drug, Right Patient, Right Time: Cases in “Precisionalised” Treatment of Advanced NSCLC

PeerVoice Heart & Lung Audio

Play Episode Listen Later Sep 29, 2022 27:59


Right Drug, Right Patient, Right Time: Cases in “Precisionalised” Treatment of Advanced NSCLC

PeerVoice Clinical Pharmacology Audio
New Biomarkers, New Targets in Advanced NSCLC

PeerVoice Clinical Pharmacology Audio

Play Episode Listen Later Aug 17, 2022 20:20


New Biomarkers, New Targets in Advanced NSCLC

PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast
Mark A. Socinski, MD - Expanding Options, Lingering Questions: How to Select the Right Immunotherapy for First-Line Treatment of Advanced NSCLC

PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast

Play Episode Listen Later May 23, 2022 70:25


Go online to PeerView.com/JBW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immune checkpoint inhibitors (ICIs) comprise a critical component of the treatment arsenal for advanced/metastatic non–small cell lung cancer (NSCLC), with numerous single-agent and combination options approved for use in the first-line setting. Despite the availability of a broad array of immunotherapy options, not all patients benefit from or have access to these agents, especially those in underserved populations and communities. Innovative solutions are needed to help address some of the challenges and improve access to level the playing field for more patients with advanced/metastatic NSCLC. In this educational activity based on a recent web broadcast, experts provide useful clinical updates and multifaceted practical guidance for navigating the multitude of immunotherapy options for newly diagnosed patients with advanced/metastatic NSCLC. Upon completion of this activity, participants should be better able to: Compare the characteristics of available and emerging immunotherapy-based strategies for first-line treatment of advanced/metastatic nonsquamous NSCLC, Individualize first-line selection of immunotherapies or combinations for patients with advanced/metastatic NSCLC based on all relevant factors related to the tumor, disease, patient, and treatment, Implement patient-centric, team-based approaches to integrate immunotherapy for eligible patients with advanced/metastatic nonsquamous NSCLC, considering current evidence and guidelines, including the applicability and implications of data from different patient populations.

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
Mark A. Socinski, MD - Expanding Options, Lingering Questions: How to Select the Right Immunotherapy for First-Line Treatment of Advanced NSCLC

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Play Episode Listen Later May 23, 2022 70:16


Go online to PeerView.com/JBW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immune checkpoint inhibitors (ICIs) comprise a critical component of the treatment arsenal for advanced/metastatic non–small cell lung cancer (NSCLC), with numerous single-agent and combination options approved for use in the first-line setting. Despite the availability of a broad array of immunotherapy options, not all patients benefit from or have access to these agents, especially those in underserved populations and communities. Innovative solutions are needed to help address some of the challenges and improve access to level the playing field for more patients with advanced/metastatic NSCLC. In this educational activity based on a recent web broadcast, experts provide useful clinical updates and multifaceted practical guidance for navigating the multitude of immunotherapy options for newly diagnosed patients with advanced/metastatic NSCLC. Upon completion of this activity, participants should be better able to: Compare the characteristics of available and emerging immunotherapy-based strategies for first-line treatment of advanced/metastatic nonsquamous NSCLC, Individualize first-line selection of immunotherapies or combinations for patients with advanced/metastatic NSCLC based on all relevant factors related to the tumor, disease, patient, and treatment, Implement patient-centric, team-based approaches to integrate immunotherapy for eligible patients with advanced/metastatic nonsquamous NSCLC, considering current evidence and guidelines, including the applicability and implications of data from different patient populations.

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast
Mark A. Socinski, MD - Expanding Options, Lingering Questions: How to Select the Right Immunotherapy for First-Line Treatment of Advanced NSCLC

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast

Play Episode Listen Later May 23, 2022 70:25


Go online to PeerView.com/JBW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immune checkpoint inhibitors (ICIs) comprise a critical component of the treatment arsenal for advanced/metastatic non–small cell lung cancer (NSCLC), with numerous single-agent and combination options approved for use in the first-line setting. Despite the availability of a broad array of immunotherapy options, not all patients benefit from or have access to these agents, especially those in underserved populations and communities. Innovative solutions are needed to help address some of the challenges and improve access to level the playing field for more patients with advanced/metastatic NSCLC. In this educational activity based on a recent web broadcast, experts provide useful clinical updates and multifaceted practical guidance for navigating the multitude of immunotherapy options for newly diagnosed patients with advanced/metastatic NSCLC. Upon completion of this activity, participants should be better able to: Compare the characteristics of available and emerging immunotherapy-based strategies for first-line treatment of advanced/metastatic nonsquamous NSCLC, Individualize first-line selection of immunotherapies or combinations for patients with advanced/metastatic NSCLC based on all relevant factors related to the tumor, disease, patient, and treatment, Implement patient-centric, team-based approaches to integrate immunotherapy for eligible patients with advanced/metastatic nonsquamous NSCLC, considering current evidence and guidelines, including the applicability and implications of data from different patient populations.

PeerView Internal Medicine CME/CNE/CPE Video Podcast
Mark A. Socinski, MD - Expanding Options, Lingering Questions: How to Select the Right Immunotherapy for First-Line Treatment of Advanced NSCLC

PeerView Internal Medicine CME/CNE/CPE Video Podcast

Play Episode Listen Later May 23, 2022 70:25


Go online to PeerView.com/JBW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immune checkpoint inhibitors (ICIs) comprise a critical component of the treatment arsenal for advanced/metastatic non–small cell lung cancer (NSCLC), with numerous single-agent and combination options approved for use in the first-line setting. Despite the availability of a broad array of immunotherapy options, not all patients benefit from or have access to these agents, especially those in underserved populations and communities. Innovative solutions are needed to help address some of the challenges and improve access to level the playing field for more patients with advanced/metastatic NSCLC. In this educational activity based on a recent web broadcast, experts provide useful clinical updates and multifaceted practical guidance for navigating the multitude of immunotherapy options for newly diagnosed patients with advanced/metastatic NSCLC. Upon completion of this activity, participants should be better able to: Compare the characteristics of available and emerging immunotherapy-based strategies for first-line treatment of advanced/metastatic nonsquamous NSCLC, Individualize first-line selection of immunotherapies or combinations for patients with advanced/metastatic NSCLC based on all relevant factors related to the tumor, disease, patient, and treatment, Implement patient-centric, team-based approaches to integrate immunotherapy for eligible patients with advanced/metastatic nonsquamous NSCLC, considering current evidence and guidelines, including the applicability and implications of data from different patient populations.

PeerView Internal Medicine CME/CNE/CPE Audio Podcast
Mark A. Socinski, MD - Expanding Options, Lingering Questions: How to Select the Right Immunotherapy for First-Line Treatment of Advanced NSCLC

PeerView Internal Medicine CME/CNE/CPE Audio Podcast

Play Episode Listen Later May 23, 2022 70:16


Go online to PeerView.com/JBW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immune checkpoint inhibitors (ICIs) comprise a critical component of the treatment arsenal for advanced/metastatic non–small cell lung cancer (NSCLC), with numerous single-agent and combination options approved for use in the first-line setting. Despite the availability of a broad array of immunotherapy options, not all patients benefit from or have access to these agents, especially those in underserved populations and communities. Innovative solutions are needed to help address some of the challenges and improve access to level the playing field for more patients with advanced/metastatic NSCLC. In this educational activity based on a recent web broadcast, experts provide useful clinical updates and multifaceted practical guidance for navigating the multitude of immunotherapy options for newly diagnosed patients with advanced/metastatic NSCLC. Upon completion of this activity, participants should be better able to: Compare the characteristics of available and emerging immunotherapy-based strategies for first-line treatment of advanced/metastatic nonsquamous NSCLC, Individualize first-line selection of immunotherapies or combinations for patients with advanced/metastatic NSCLC based on all relevant factors related to the tumor, disease, patient, and treatment, Implement patient-centric, team-based approaches to integrate immunotherapy for eligible patients with advanced/metastatic nonsquamous NSCLC, considering current evidence and guidelines, including the applicability and implications of data from different patient populations.

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast
Mark A. Socinski, MD - Expanding Options, Lingering Questions: How to Select the Right Immunotherapy for First-Line Treatment of Advanced NSCLC

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast

Play Episode Listen Later May 23, 2022 70:16


Go online to PeerView.com/JBW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immune checkpoint inhibitors (ICIs) comprise a critical component of the treatment arsenal for advanced/metastatic non–small cell lung cancer (NSCLC), with numerous single-agent and combination options approved for use in the first-line setting. Despite the availability of a broad array of immunotherapy options, not all patients benefit from or have access to these agents, especially those in underserved populations and communities. Innovative solutions are needed to help address some of the challenges and improve access to level the playing field for more patients with advanced/metastatic NSCLC. In this educational activity based on a recent web broadcast, experts provide useful clinical updates and multifaceted practical guidance for navigating the multitude of immunotherapy options for newly diagnosed patients with advanced/metastatic NSCLC. Upon completion of this activity, participants should be better able to: Compare the characteristics of available and emerging immunotherapy-based strategies for first-line treatment of advanced/metastatic nonsquamous NSCLC, Individualize first-line selection of immunotherapies or combinations for patients with advanced/metastatic NSCLC based on all relevant factors related to the tumor, disease, patient, and treatment, Implement patient-centric, team-based approaches to integrate immunotherapy for eligible patients with advanced/metastatic nonsquamous NSCLC, considering current evidence and guidelines, including the applicability and implications of data from different patient populations.

PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast
Pasi A. Jänne, MD, PhD - Addressing Key Targets in Advanced NSCLC: Evaluating the Latest Evidence and Clinical Opportunities for HER2-, HER3-, and TROP2-Targeted Therapies

PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast

Play Episode Listen Later Apr 29, 2022 58:28


Go online to PeerView.com/ZGP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The treatment arsenal for non–small cell lung cancer (NSCLC) with and without genomic alterations continues to expand, and novel HER2-, HER3-, and TROP2-targeting antibody–drug conjugates (ADCs) are showing great promise in improving outcomes in patients who currently have limited options. How should patients who would benefit from these novel ADCs be identified, and does biomarker testing have a role? Where do the HER2-, HER3-, and TROP2-targeting therapies fit within the current treatment arsenal for advanced/metastatic NSCLC, and what is the best way to integrate them into practice? These and other questions are addressed by top experts in this PeerView MasterClass and Practicum. Faculty navigate through the evidence base, provide practical guidance regarding the clinical role and integration of novel ADCs, and discuss illustrative cases to help you better understand how to translate the science to practice and improve patient outcomes. Upon completion of this activity, participants should be better able to: Discuss the clinical importance and biologic rationale for targeting of HER2, HER3, and TROP2 alterations with novel therapies in lung cancer, Review current guidelines and best practices for biomarker testing in patients with NSCLC, Summarize the characteristics, mechanisms of action, latest safety and efficacy findings, and recommendations of emerging HER2-, HER3-, and TROP2-targeted therapies in NSCLC, Integrate individualized treatment plans through different lines of therapy for patients with NSCLC that take into consideration appropriate strategies for biomarker testing/interpretation to identify patients who might benefit from emerging HER2-, HER3-, and TROP2-targeted therapies.

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
Pasi A. Jänne, MD, PhD - Addressing Key Targets in Advanced NSCLC: Evaluating the Latest Evidence and Clinical Opportunities for HER2-, HER3-, and TROP2-Targeted Therapies

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Apr 29, 2022 57:55


Go online to PeerView.com/ZGP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The treatment arsenal for non–small cell lung cancer (NSCLC) with and without genomic alterations continues to expand, and novel HER2-, HER3-, and TROP2-targeting antibody–drug conjugates (ADCs) are showing great promise in improving outcomes in patients who currently have limited options. How should patients who would benefit from these novel ADCs be identified, and does biomarker testing have a role? Where do the HER2-, HER3-, and TROP2-targeting therapies fit within the current treatment arsenal for advanced/metastatic NSCLC, and what is the best way to integrate them into practice? These and other questions are addressed by top experts in this PeerView MasterClass and Practicum. Faculty navigate through the evidence base, provide practical guidance regarding the clinical role and integration of novel ADCs, and discuss illustrative cases to help you better understand how to translate the science to practice and improve patient outcomes. Upon completion of this activity, participants should be better able to: Discuss the clinical importance and biologic rationale for targeting of HER2, HER3, and TROP2 alterations with novel therapies in lung cancer, Review current guidelines and best practices for biomarker testing in patients with NSCLC, Summarize the characteristics, mechanisms of action, latest safety and efficacy findings, and recommendations of emerging HER2-, HER3-, and TROP2-targeted therapies in NSCLC, Integrate individualized treatment plans through different lines of therapy for patients with NSCLC that take into consideration appropriate strategies for biomarker testing/interpretation to identify patients who might benefit from emerging HER2-, HER3-, and TROP2-targeted therapies.

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast
Pasi A. Jänne, MD, PhD - Addressing Key Targets in Advanced NSCLC: Evaluating the Latest Evidence and Clinical Opportunities for HER2-, HER3-, and TROP2-Targeted Therapies

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast

Play Episode Listen Later Apr 29, 2022 58:28


Go online to PeerView.com/ZGP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The treatment arsenal for non–small cell lung cancer (NSCLC) with and without genomic alterations continues to expand, and novel HER2-, HER3-, and TROP2-targeting antibody–drug conjugates (ADCs) are showing great promise in improving outcomes in patients who currently have limited options. How should patients who would benefit from these novel ADCs be identified, and does biomarker testing have a role? Where do the HER2-, HER3-, and TROP2-targeting therapies fit within the current treatment arsenal for advanced/metastatic NSCLC, and what is the best way to integrate them into practice? These and other questions are addressed by top experts in this PeerView MasterClass and Practicum. Faculty navigate through the evidence base, provide practical guidance regarding the clinical role and integration of novel ADCs, and discuss illustrative cases to help you better understand how to translate the science to practice and improve patient outcomes. Upon completion of this activity, participants should be better able to: Discuss the clinical importance and biologic rationale for targeting of HER2, HER3, and TROP2 alterations with novel therapies in lung cancer, Review current guidelines and best practices for biomarker testing in patients with NSCLC, Summarize the characteristics, mechanisms of action, latest safety and efficacy findings, and recommendations of emerging HER2-, HER3-, and TROP2-targeted therapies in NSCLC, Integrate individualized treatment plans through different lines of therapy for patients with NSCLC that take into consideration appropriate strategies for biomarker testing/interpretation to identify patients who might benefit from emerging HER2-, HER3-, and TROP2-targeted therapies.

PeerView Internal Medicine CME/CNE/CPE Video Podcast
Pasi A. Jänne, MD, PhD - Addressing Key Targets in Advanced NSCLC: Evaluating the Latest Evidence and Clinical Opportunities for HER2-, HER3-, and TROP2-Targeted Therapies

PeerView Internal Medicine CME/CNE/CPE Video Podcast

Play Episode Listen Later Apr 29, 2022 58:28


Go online to PeerView.com/ZGP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The treatment arsenal for non–small cell lung cancer (NSCLC) with and without genomic alterations continues to expand, and novel HER2-, HER3-, and TROP2-targeting antibody–drug conjugates (ADCs) are showing great promise in improving outcomes in patients who currently have limited options. How should patients who would benefit from these novel ADCs be identified, and does biomarker testing have a role? Where do the HER2-, HER3-, and TROP2-targeting therapies fit within the current treatment arsenal for advanced/metastatic NSCLC, and what is the best way to integrate them into practice? These and other questions are addressed by top experts in this PeerView MasterClass and Practicum. Faculty navigate through the evidence base, provide practical guidance regarding the clinical role and integration of novel ADCs, and discuss illustrative cases to help you better understand how to translate the science to practice and improve patient outcomes. Upon completion of this activity, participants should be better able to: Discuss the clinical importance and biologic rationale for targeting of HER2, HER3, and TROP2 alterations with novel therapies in lung cancer, Review current guidelines and best practices for biomarker testing in patients with NSCLC, Summarize the characteristics, mechanisms of action, latest safety and efficacy findings, and recommendations of emerging HER2-, HER3-, and TROP2-targeted therapies in NSCLC, Integrate individualized treatment plans through different lines of therapy for patients with NSCLC that take into consideration appropriate strategies for biomarker testing/interpretation to identify patients who might benefit from emerging HER2-, HER3-, and TROP2-targeted therapies.

Cancer Buzz
QI in Advanced NSCLC

Cancer Buzz

Play Episode Listen Later Nov 18, 2021 15:58


To support the optimization of care for patients with advanced non-small cell lung cancer (NSCLC), six ACCC Cancer Program Members applied to participate in a process improvement initiative. Hear from Wendi Waugh, Director of Cancer Services, Southern Ohio Medical Center, as she walks us through the design and implementation of their plan, which focused on the need to better understand the causes of potentially preventable emergency department visits among patients with NSCLC who are undergoing active treatment. She'll then share her three tips for cancer programs who may consider a quality improvement approach to reviewing and improving their care processes. Guest: Wendi Waugh, BS, RT(R)(T), CMD, CTR Administrative Director of Cancer Services & Community Health and Wellness Southern Ohio Medical Center Related Content: Fostering Excellence in Care and Outcomes in Patients with Stage III and IV NSCLC National NSCLC Quality Care Initiative NSCLC Resource Library 6 Steps to Improve Care Coordination for Lung Cancer Patients [PODCAST] Ep 24: Improving Lung Cancer Care Biomarker Testing Implementation Roadmap for Advanced Non-Small Cell Lung Cancer (NSCLC) Key Takeaways in Biomarker Testing, Patient Safety, Care Coordination, and Clinical Research for NSCLC Advanced NSCLC Biomarker Testing (CME/CMLE on-demand course)